

# Alison Haywood

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4959617/publications.pdf>

Version: 2024-02-01

52  
papers

841  
citations

430442

18  
h-index

552369

26  
g-index

54  
all docs

54  
docs citations

54  
times ranked

1029  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of polymorphisms in <i>ARRB2</i> and clinical response to methadone for pain in advanced cancer. <i>Pharmacogenomics</i> , 2022, 23, 281-289.	0.6	2
2	Practitioners' Perspective on Metabolic Monitoring of Second-Generation Antipsychotics: Existing Gaps in Knowledge, Barriers to Monitoring, and Strategies. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2022, 32, 296-303.	0.7	1
3	Corticosteroids for the management of cancer-related pain in adults. <i>The Cochrane Library</i> , 2021, 2021, CD010756.	1.5	43
4	Practice review: Evidence-based quality use of corticosteroids in the palliative care of patients with advanced cancer. <i>Palliative Medicine</i> , 2021, 35, 461-472.	1.3	11
5	Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related) Tj ETQq1 1 0.784314 rgBT /Overlo	1.5	19
6	Paper based vs. electronic records for clinical audit: Evidence of documentation of medication safety monitoring in youth prescribed antipsychotics. <i>Children and Youth Services Review</i> , 2020, 109, 104666.	1.0	1
7	Corticosteroids for the management of cancer-related fatigue in adults with advanced cancer. <i>The Cochrane Library</i> , 2020, , .	1.5	0
8	Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). <i>Trials</i> , 2020, 21, 611.	0.7	21
9	Systemic corticosteroids for the management of cancer-related breathlessness (dyspnoea) in adults. <i>The Cochrane Library</i> , 2019, 2, CD012704.	1.5	13
10	Current pharmacotherapy options for conduct disorders in adolescents and children. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 571-583.	0.9	6
11	Managing diabetes at the end of life – a retrospective chart audit of two health providers in Queensland, Australia. <i>Progress in Palliative Care</i> , 2019, 27, 51-57.	0.7	0
12	Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD). <i>BMC Palliative Care</i> , 2019, 18, 110.	0.8	31
13	Enhancement and Suppression of Ionization in Drug Analysis Using HPLC-MS/MS in Support of Therapeutic Drug Monitoring: A Review of Current Knowledge of Its Minimization and Assessment: Erratum. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 284-284.	1.0	45
14	59 – Metabolic monitoring of youth prescribed antipsychotics: the evidence gap widens in failing to provide reasonable standard of physical healthcare. , 2018, , .		0
15	Micronutrient Therapy for Violent and Aggressive Male Youth: An Open-Label Trial. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 823-832.	0.7	16
16	Instruments for evaluating pharmacotherapy intervention efficacy in violent and aggressive behavior and conduct disorder in youth. <i>Aggression and Violent Behavior</i> , 2017, 34, 84-95.	1.2	4
17	Can Saliva and Plasma Methadone Concentrations Be Used for Enantioselective Pharmacokinetic and Pharmacodynamic Studies in Patients With Advanced Cancer?. <i>Clinical Therapeutics</i> , 2017, 39, 1840-1848.	1.1	6
18	Critical assessment of thioguanine treatment for inflammatory bowel diseases: Is it time to rehabilitate this treatment?. <i>Journal of Digestive Diseases</i> , 2017, 18, 529-536.	0.7	5

#	ARTICLE	IF	CITATIONS
19	Systemic corticosteroids for the management of cancer-related breathlessness (dyspnoea) in adults. The Cochrane Library, 2017, , .	1.5	2
20	Comparison between self-compounded and compounded dexamethasone mouth rinse for oral lichen planus: a pilot, randomized, crossover trial. Journal of Investigative and Clinical Dentistry, 2017, 8, e12225.	1.8	13
21	Evidence of Stability of Medicines Repackaged in Compliance Aids: A Review. Current Drug Safety, 2016, 11, 69-77.	0.3	16
22	Exposure to Fentanyl After Transdermal Patch Administration for Cancer Pain Management. Journal of Clinical Pharmacology, 2016, 56, 705-713.	1.0	5
23	Pharmacotherapy of conduct disorder: Challenges, options and future directions. Journal of Psychopharmacology, 2016, 30, 967-975.	2.0	10
24	Quantitative determination of the enantiomers of methadone in human plasma and saliva by chiral column chromatography coupled with mass spectrometric detection. Talanta, 2016, 149, 142-148.	2.9	19
25	Saliva versus Plasma for Pharmacokinetic and Pharmacodynamic Studies of Fentanyl in Patients with Cancer. Clinical Therapeutics, 2015, 37, 2882-2883.	1.1	5
26	Repackaged sodium valproate tablets " Meeting quality and adherence to ensure seizure control. Seizure: the Journal of the British Epilepsy Association, 2015, 31, 108-111.	0.9	11
27	Validation of a Fentanyl Transdermal Adhesion Scoring Tool for Use in Clinical Practice. Journal of Pain and Symptom Management, 2015, 49, 934-938.	0.6	3
28	Saliva versus Plasma for Pharmacokinetic and Pharmacodynamic Studies of Fentanyl in Patients with Cancer. Clinical Therapeutics, 2015, 37, 2468-2475.	1.1	16
29	Protein binding of fentanyl and its metabolite nor-fentanyl in human plasma, albumin and $\alpha$ -1 acid glycoprotein. Xenobiotica, 2015, 45, 207-212.	0.5	20
30	Therapeutic Challenges in Cancer Pain Management: A Systematic Review of Methadone. Journal of Pain and Palliative Care Pharmacotherapy, 2014, 28, 197-205.	0.5	33
31	Development, validation and application of an HPLC-MS/MS method for the determination of fentanyl and nor-fentanyl in human plasma and saliva. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 960, 27-33.	1.2	32
32	Extemporaneous compounding in veterinary practice: A New Zealand perspective. New Zealand Veterinary Journal, 2013, 61, 311-315.	0.4	6
33	Stability of Paracetamol Tablets Repackaged in Dose Administration Aids for Use: Implications for Practice. Journal of Pharmacy Practice and Research, 2013, 43, 218-220.	0.5	6
34	Liquid Dosage Forms Extemporaneously Prepared from Commercially Available Products " Considering New Evidence on Stability. Journal of Pharmacy and Pharmaceutical Sciences, 2013, 16, 441.	0.9	42
35	Stability of Dispersible Aspirin Tablets Repacked into Dosette Boxes. Journal of Pharmacy Practice and Research, 2012, 42, 204-207.	0.5	13
36	A stable-isotope HPLC-MS/MS method to simplify storage of human whole blood samples for glutathione assay. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 898, 136-140.	1.2	17

#	ARTICLE	IF	CITATIONS
37	Clozapine repackaged into dose administration aids: a common practice in Australian hospitals. <i>International Journal of Pharmacy Practice</i> , 2012, 20, 4-8.	0.3	10
38	Pharmaceutical excipients “ where do we begin?. <i>Australian Prescriber</i> , 2011, 34, 112-114.	0.5	50
39	Dose administration aids: Pharmacists’s™ role in improving patient care. <i>Australasian Medical Journal</i> , 2011, 4, 183-189.	0.1	16
40	Promoting and Providing Expert Guidance in Work-intensive Clinical Settings. <i>Vocations and Learning</i> , 2010, 3, 141-156.	0.9	16
41	Compliance Aids and Medicine Stability: New Evidence of Quality Assurance. <i>Current Drug Safety</i> , 2009, 4, 74-78.	0.3	22
42	Prochlorperazine tablets repackaged into dose administration aids: can the patient be assured of quality?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2009, 34, 161-169.	0.7	17
43	Solid Medication Dosage Form Modification at the Bedside and in the Pharmacy of Queensland Hospitals. <i>Journal of Pharmacy Practice and Research</i> , 2009, 39, 129-134.	0.5	38
44	Compounding solutions for exotic and nondomesticated fauna in australia: an investigative study. <i>International Journal of Pharmaceutical Compounding</i> , 2009, 11, 440-4.	0.0	0
45	Stability of melatonin in an extemporaneously compounded sublingual solution and hard gelatin capsule. <i>International Journal of Pharmaceutical Compounding</i> , 2009, 13, 170-4.	0.0	2
46	Managing Extemporaneous Oral Liquids in Practice. <i>Journal of Pharmacy Practice and Research</i> , 2007, 37, 131-133.	0.5	5
47	Stability of Frusemide Tablets Repackaged in Dose Administration Aids. <i>Journal of Pharmacy Practice and Research</i> , 2007, 37, 178-181.	0.5	24
48	Boosting morale and improving performance in the nursing setting. <i>Journal of Nursing Management</i> , 2007, 15, 811-816.	1.4	21
49	Stability Implications of Repackaging Paracetamol Tablets into Dose Administration Aids. <i>Journal of Pharmacy Practice and Research</i> , 2006, 36, 25-28.	0.5	22
50	Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2006, 9, 398-426.	0.9	63
51	Extemporaneous Isoniazid Mixture: Stability Implications. <i>Journal of Pharmacy Practice and Research</i> , 2005, 35, 181-182.	0.5	19
52	Title is missing!. <i>Journal of Chemical Crystallography</i> , 1999, 29, 435-447.	0.5	21